Laser in situ keratomileusis for high myopia with the VISX Star laser

• Published in: Ophthalmology (Rochester, Minn.) Vol. 107; no. 4; pp. 653 - 661
• Main Authors: Kawesch, Gary M, Kezirian, Guy M
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01.04.2000; Elsevier
• Subjects: Adult; Biological and medical sciences; Cornea - physiopathology; Cornea - surgery; Female; Follow-Up Studies; Humans; Keratomileusis, Laser In Situ; Male; Medical sciences; Myopia - physiopathology; Myopia - surgery; Refraction, Ocular - physiology; Reoperation; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases; Surgery of the eye and orbit; Treatment Outcome; Visual Acuity - physiology; High; Human; Keratomileusis; Vision disorder; Treatment efficiency; In situ; Myopia; Eye; Eye disease; Treatment; Surgery; Refractive error; Laser; Apparatus; Severe; Comparative study
• DOI: 10.1016/S0161-6420(99)00148-7
• ISSN: 0161-6420

To evaluate the results of laser in situ keratomileusis (LASIK) for spherical and spherocylindrical myopia (range, 9–22 diopters [D]) with the VISX Star laser, (VISX Inc., Santa Clara, CA). Non-comparative, single-surgeon interventional case series. Two hundred ninety eyes of 175 patients. Consecutive patients who underwent LASIK in the study range with the VISX Star laser were evaluated for early (approximately 1 month) and late (after 9 months) outcomes. Both single procedure outcomes and results after reoperation for refractive enhancement were included. Outcome measures included uncorrected visual acuity, manifest refraction, refractive predictability, refractive stability, best spectacle-corrected visual acuity (BSCVA), results of reoperations, and complications. At the early postoperative examination, approximately 1 month after surgery, 285 of 290 eyes (98.3%) were examined. Uncorrected visual acuity of 20/40 or better occurred in 209 of 285 (73.3%) eyes, and 198 of 285 (69.5%) eyes had a manifest spheroequivalent between ±1.00 D. Subsequently, 60 eyes (20.7%) underwent reoperation for refractive enhancement. Late results, beyond 8 months from the initial surgery and including reoperations, were available in 195 of 290 eyes (67.2%). Uncorrected visual acuity results of 20/40 or better were found in 166 of 195 eyes (85.1%) and of 20/25 or better in 99 of 195 eyes (50.8%). Manifest spheroequivalent results were ±2.00 D in 187 of 195 eyes (95.9%) and ±1.00 D in 148 of 195 eyes (75.9%). In a paired-cohort analysis of 131 single-procedure eyes seen at both intervals, refractive stability (change in manifest refractive spheroequivalent of less than 1.00 D) was present in 101 of 131 eyes (77.1%) between the two observation intervals. Overall, approximately 3.6% eyes lost 2 lines or more of BSCVA, and other complications (flap wrinkling and epithelial ingrowth) were reported in 2% of eyes. Improvement in BSCVA of 1 line or more occurred in 5.6% eyes. Laser in situ keratomileusis for high myopia with the VISX Star laser provided satisfactory refractive and visual results that compare well with other reports in the literature. Subjective results and other measures of visual function need further evaluation.